Key Takeaways
- Volumes, not unit economics, drove the miss: Revenue fell to INR557 crores as export volumes dropped ~9% YoY, while per-kg gross contribution sat mid-range versus recent quarters.
- Export demand stays soft into Q2: Management sees Q2 exports similar to Q1, with freight rates spiking to COVID-era levels and container availability tight; a pickup is expected only from Q3.
- Gross margins are quietly improving: Standalone gross margin reached ~34.1%, up quarter-on-quarter, benefiting from lower API prices; management sees scope for another 1% improvement if demand cooperates.
- Capacity expansion is the H2 story: The Saykha greenfield project and Baddi brownfield expansion both come online by end-Q2, setting up a 50% YoY H2 jump in specialty chemicals and mid-teens API volume growth.
- What to watch next quarter: Whether export demand stabilizes enough to let the new capacity translate into revenue, and whether gross margins can inch toward the ~35% target.
Revenue & Volume: The Export Drag
- Export volumes, not prices, broke the quarter: Domestic volume was flat YoY, but export volume fell ~9%, driven by political uncertainty and government tender cycles in buyer countries, plus a fire at the Tarapur N-198 unit that disrupted one anti-inflammatory product's dispatches.
- Price decline was a timing artifact: Export orders executed in the March quarter were booked in the December quarter when prices were higher; the subsequent price decline hit Q1 revenue as those higher-priced orders cleared.
- Formulation exports were a bright spot, up 33% YoY: Growth came from a strategic pivot toward international markets, new product registrations, and entry into new geographies, though sales were constrained by a one-month shutdown for brownfield expansion and major audits.
- Q2 export outlook is subdued: Freight rates have surged back to COVID-era levels and container availability is tight, unrelated to Red Sea disruptions. Management expects Q2 exports to look similar to Q1, with demand picking up from Q3.
Harit Pragji Shah: "Export for the Q2 also we subdued demand as of now. And moreover, there is freight rates have just moved up again like COVID levels -- some containers are not available, and all that situation is there. So it's not related to Red Sea actually, but some other things. So overall, we feel Q2 will be similar to Q1 in exports and the demand will start coming up from Q3, it looks like as of now."
Margins: Gross Margin Progress, Operating Leverage Pain
- Gross margin improved as API prices fell: Standalone gross margin reached ~34.1%, up from the March quarter, because lower API prices reduce input costs and widen gross contribution. Management believes another ~1% improvement is possible if demand firms up.
- Per-unit profitability was not the problem: On a per-kg basis, gross contribution sat in the middle of the last five quarters, with some products at their best levels in five quarters and others average. The quarter's shortfall was purely a volume story.
- Operating leverage went the wrong way: Lower volumes meant fixed costs spread over fewer units; management estimates that with decent volumes, EBITDA margin would have reached at least 14% this quarter.
- Export mix shift is a structural margin headwind: Export share of standalone sales has fallen from 38-40% pre-COVID to 31-33%, and since exports carry higher gross contribution, this mix shift has depressed blended margins relative to historical levels.
Adhish Patil: "The main problem what happened this particular quarter was lack in volumes."
Adhish Patil: "What we feel, had our volumes being decently good, probably we would have achieved around -- at least 14% EBITDA margin for this quarter, if our volumes were good."
Capacity Expansion: The H2 Growth Engine
- Saykha greenfield project goes live by end-Q2: The Gujarat facility for specialty chemicals and intermediates will increase spec-chem production capacity and enable backward integration for diabetic products, improving margins in H2.
- Baddi brownfield expansion doubles capacity over 12-15 months: A 15-20% capacity increase arrives next quarter, with capacity nearly doubling over the following year, supporting the formulation export push.
- Metformin capacity is expanding via process change: Monthly capacity moves from 1,400-1,500 tons to 1,700-1,800 tons; validation batches are complete, pending environmental approvals and customer migration to the new process.
- Dermatology facility began production last quarter: The Tarapur dermatology unit commenced production and is expected to ramp up progressively over the next two quarters.
Specialty Chemicals & New Products
- H2 specialty chemicals growth target is 50% YoY: Driven entirely by the Saykha project coming online; management expects the segment to contribute meaningfully from September onward.
- 15 oncology products in development for regulated markets: Launches are planned over the next 2-3 financial years, with initial sales expected from FY26 and the majority from FY27.
- Formulation strategy is pivoting to exports: The company is deliberately reducing domestic formulation business and growing international sales, including toll manufacturing for more strategic products, because exports are the margin driver.
Pricing & Rate Variance
- API prices are at a floor and stable: Prices have been at bottom levels for one quarter and are expected to remain stable through Q2.
- Negative rate variance persists through H1, then fades: Because prices fell sharply in the December and March quarters, H1 FY25 will show negative rate variance YoY; the comps ease in H2 as the base resets to lower price levels.
- Price growth expectations have moderated: Management had originally expected ~8-10% price growth for H1; Q1 took the biggest hit, and Q2's YoY price variation will be smaller because September 2024 prices compare against already-declined September 2023 levels.
Adhish Patil: "So basically, the export which happened in March quarter those are the orders taken in the December quarter when the prices were high. So those orders got executed in March quarter."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | Upwards of ₹4,000 crores (assumes current prices) | FY27 |
| API volume growth | High single-digit full year; H1 flattish, H2 mid-teens YoY | FY25 |
| Specialty chemicals growth | 50% YoY growth in H2, driven by Saykha project | H2 FY25 |
| Standalone gross margin | Reach ~35% (from ~34.1% currently), demand-dependent | No fixed date |
| Saykha greenfield project | Commence operations | End of Q2 FY25 |
| Baddi brownfield expansion | Increase capacity 15-20% in the next quarter; nearly double over 12-15 months | Q2 FY25 / FY26 |
| Dermatology facility ramp-up | Progressive production ramp-up | Next two quarters |
| Oncology product launches | Initial sales from FY26, majority from FY27 | FY26-FY27 |
| Export demand recovery | Demand expected to pick up | From Q3 FY25 |
| Negative rate variance | Variance disappears as base resets | H2 FY25 |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹557 cr, down 16% YoY; 11% of decline from negative price variance |
| EBITDA | ₹66 cr, with EBITDA margin at 11.9% |
| PAT | ₹33 cr |
| Gross margin (standalone) | 34.1%, improved vs March 2024 quarter; target of ~35% |
| Formulation segment revenue | ₹70.4 cr, up 4.2% QoQ |
| Formulation exports share | 57% of total formulations revenue |
| API export volume change | Down ~8% YoY |
| API domestic price variance | Down a little upwards of 12% YoY |
| API export price variance | Down ~9% YoY |
| Dermatology scale-up impact | ₹6 cr negative impact at PBT level; ₹3.5 cr at EBITDA, ₹2.5 cr post-EBITDA |
| Capex incurred during quarter | ₹52 cr, mainly towards capacity expansion, backward integration, and new formulation launches |
| Full-year capex guidance | ₹200 cr, funded through internal accruals and partly through term loans |
| FY27 revenue guidance | Upwards of ₹4,000 cr, assuming current prices |
| Specialty Chemicals H2 growth expectation | 50% YoY growth in second half of FY25 |
| Metformin capacity | 1,400–1,500 tons per month, increasing to 1,700–1,800 tons per month |
| Oncology peak revenue budget | ₹300–400 cr, over next 2–3 years |